Uncategorized

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

Published

on

AbbVie scooped up immunology player Apogee Therapeutics for nearly $11 billion in one of the year’s top deals to-date, while Sanofi made a big play to survive its upcoming Dupixent patent cliff; FDA uncertainty continues as the agency changes direction on gene therapies by uniQure and REGENXBIO; and Jef Akst and Annalee Armstrong report back from San Diego.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version